Brand tirzepatide
Sold by GoodRx · Injection, pen · every brand tirzepatide record
What you actually pay
Per month
$338
| Medication · KwikPen, starting price | $299 |
|---|---|
| Required membership | $39 |
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| KwikPen, starting price “As low as $ 299 per month 3 New Zepbound® KwikPen®” | Per month$299 | Charged today$299 |
We earn nothing from this link. GoodRx has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
One reading so far. A price history appears here after the next verification pass.
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Cancellation | “GoodRx is NOT insurance. Cancel anytime.” |
|---|---|
| Membership | Required. $39 per month. “$39/mo. to start your weight loss treatment Get online care and ongoing support to help you reach your most effective GLP-1 dose. Get started now Medication cost not included.” |
Not yet checked: pharmacy, states, prescriber and consult fee.
Recorded from goodrx.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2, 2026 — This is a near-textbook case of the membership-vs-price trap the brief warns about: GoodRx Care Direct charges $39/mo for the care subscription, explicitly labeled 'Medication cost not included,' with the GLP-1 medication itself priced separately ($149-$299/mo depending on drug and form). GoodRx also sells Foundayo (orforglipron), outside this register's drug enum, and separately runs a pharmacy-discount-coupon program (e.g., 'Wegovy $1,638.99 retail ... $149.00') that is a different product from the GoodRx Care Direct telehealth subscription — only Care Direct subscription prices were recorded here to avoid conflating the two.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.